Analyst Price Target is $47.00
▲ +67.86% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Metsera in the last 3 months. The average price target is $47.00, with a high forecast of $56.00 and a low forecast of $38.00. The average price target represents a 67.86% upside from the last price of $28.00.
Current Consensus is
Buy
The current consensus among 4 polled investment analysts is to buy stock in Metsera.
Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.
Read More